🇺🇸 Perflutren lipid in United States

34 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 34

Most-reported reactions

1. Back Pain — 10 reports (29.41%)
2. Dyspnoea — 7 reports (20.59%)
3. Cardio-Respiratory Arrest — 3 reports (8.82%)
4. Agitation — 2 reports (5.88%)
5. Anaphylactic Reaction — 2 reports (5.88%)
6. Arthralgia — 2 reports (5.88%)
7. Cough — 2 reports (5.88%)
8. Pain In Extremity — 2 reports (5.88%)
9. Throat Tightness — 2 reports (5.88%)
10. Unresponsive To Stimuli — 2 reports (5.88%)

Source database →

Frequently asked questions

Is Perflutren lipid approved in United States?

Perflutren lipid does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Perflutren lipid in United States?

UNC Lineberger Comprehensive Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.